Gernot Beutel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gernot Beutel has a total of 312 co-authors. Here are the top co-authors by number of shared publications:
- Arnold Ganser
Hannover Medical School, Hannover, Germany
8 shared publications - Matthias Eder
Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
6 shared publications - Jan Thomas Kielstein
Medical Clinic V, Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital, Braunschweig, Germany
5 shared publications Catherine Cordonnier
University Paris Est-Créteil, Paris, France
4 shared publications- Felicitas Thol
Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, Hannover, Germany
4 shared publications - Francesco Marchesi
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 30526
Factors associated with persistent post-COVID-19 condition and functional limitation four years after SARS-CoV-2 infection
Post-COVID-19 condition (PCC) can persist for years after acute SARS-CoV-2 infection, but factors associated with long-term persistence and functional outcomes remain incompletely understood. In this longitudinal cohort study, adults with confirmed SARS-CoV-2 infection who had volunteered for plasma donation completed surveys approximately 16 and 48 months after infection. Acute-phase demographic characteristics and symptoms were examined for associations with PCC and persistent PCC using multivariable logistic regression analyses. Persistent symptoms at follow-up and their associations with functional limitation, assessed with the Post-COVID Functional Status (PCFS) scale, were examined separately. Among 992 participants in 2021, 609 (61.4%) met criteria for PCC, while 333 of 568 participants (58.6%) fulfilled PCC criteria in 2024. Older age, fatigue, palpitations, depressive symptoms, and concentration and memory difficulties during acute infection were associated with PCC at both follow-up assessments, whereas female sex was associated with PCC only at the 4-year follow-up. Among participants with PCC in 2021, 77.4% continued to meet PCC criteria in 2024; concentration difficulties, depressive symptoms, and older age were associated with persistent PCC. Functional limitation was associated with persistent fatigue, concentration difficulties, dyspnea at rest, and depressive symptoms. These findings demonstrate the persistent nature of PCC and highlight the need for further research into the mechanisms behind PCC and the development of therapeutic strategies.
- 1 October 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 30526
Open AccessFactors associated with persistent post-COVID-19 condition and functional limitation four years after SARS-CoV-2 infection
Post-COVID-19 condition (PCC) can persist for years after acute SARS-CoV-2 infection, but factors associated with long-term persistence and functional outcomes remain incompletely understood. In this longitudinal cohort study, adults with confirmed SARS-CoV-2 infection who had volunteered for plasma donation completed surveys approximately 16 and 48 months after infection. Acute-phase demographic characteristics and symptoms were examined for associations with PCC and persistent PCC using multivariable logistic regression analyses. Persistent symptoms at follow-up and their associations with functional limitation, assessed with the Post-COVID Functional Status (PCFS) scale, were examined separately. Among 992 participants in 2021, 609 (61.4%) met criteria for PCC, while 333 of 568 participants (58.6%) fulfilled PCC criteria in 2024. Older age, fatigue, palpitations, depressive symptoms, and concentration and memory difficulties during acute infection were associated with PCC at both follow-up assessments, whereas female sex was associated with PCC only at the 4-year follow-up. Among participants with PCC in 2021, 77.4% continued to meet PCC criteria in 2024; concentration difficulties, depressive symptoms, and older age were associated with persistent PCC. Functional limitation was associated with persistent fatigue, concentration difficulties, dyspnea at rest, and depressive symptoms. These findings demonstrate the persistent nature of PCC and highlight the need for further research into the mechanisms behind PCC and the development of therapeutic strategies.
- Open Access
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy
Chronic kidney disease (CKD) before treatment and renal function decline during treatment are common in elderly patients receiving hypomethylating agents (HMAs) and venetoclax (VEN). This retrospective multicenter study of 130 newly diagnosed older acute myeloid leukemia (AML) patients evaluated the prognostic impact of renal function before and during the first treatment cycle. A total of 56 patients (43%) had CKD, and 49 (38%) developed acute kidney injury (AKI) during treatment. AKI occurrence was associated with laboratory tumor lysis syndrome (LTLS). CKD before treatment showed a trend towards a lower overall response rate (ORR, OR 0.5, p = 0.07) in multivariable analysis (MVA) and inferior relapse-free survival (RFS, HR 2.16, p = 0.06) in univariate analysis (UVA), but not MVA (RFS, HR 1.93, p = 0.15). CKD did not affect overall survival (OS) or event-free survival (EFS). AKI during HMA/VEN therapy was associated with significantly higher 30-day and 60-day mortality rates and emerged as an independent prognostic factor for inferior OS (HR 1.86, p = 0.01) and EFS (HR 1.81, p = 0.007). RFS did not differ significantly by AKI status. Sepsis was a more frequent cause of death in patients with vs. without AKI (33% vs. 5%). In conclusion, kidney function is a key prognostic factor in HMA/VEN-treated patients, warranting further study on treatment adjustments and supportive care.
Open AccessPrognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy
Chronic kidney disease (CKD) before treatment and renal function decline during treatment are common in elderly patients receiving hypomethylating agents (HMAs) and venetoclax (VEN). This retrospective multicenter study of 130 newly diagnosed older acute myeloid leukemia (AML) patients evaluated the prognostic impact of renal function before and during the first treatment cycle. A total of 56 patients (43%) had CKD, and 49 (38%) developed acute kidney injury (AKI) during treatment. AKI occurrence was associated with laboratory tumor lysis syndrome (LTLS). CKD before treatment showed a trend towards a lower overall response rate (ORR, OR 0.5, p = 0.07) in multivariable analysis (MVA) and inferior relapse-free survival (RFS, HR 2.16, p = 0.06) in univariate analysis (UVA), but not MVA (RFS, HR 1.93, p = 0.15). CKD did not affect overall survival (OS) or event-free survival (EFS). AKI during HMA/VEN therapy was associated with significantly higher 30-day and 60-day mortality rates and emerged as an independent prognostic factor for inferior OS (HR 1.86, p = 0.01) and EFS (HR 1.81, p = 0.007). RFS did not differ significantly by AKI status. Sepsis was a more frequent cause of death in patients with vs. without AKI (33% vs. 5%). In conclusion, kidney function is a key prognostic factor in HMA/VEN-treated patients, warranting further study on treatment adjustments and supportive care.
- 4 August 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2304-2305
Author’s Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al.
- 4 August 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2304-2305
Author’s Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al.
- Open Access
- 2 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2061-2071
Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)
In the post-pandemic years, SARS-CoV-2 morbidity and mortality declined due to less pathogenic variants, active and passive immunization, and antiviral therapies. However, patients with hematological malignancies and/or undergoing hematopoietic cell transplantation (HCT) remain at increased risk for poor outcomes. Therefore, adherence to contact and droplet precautions is essential to avoid transmission, especially during epidemic waves. Detection of viral RNA by nucleic acid testing of naso-oro-pharyngeal samples is the gold standard for diagnosis due to its high sensitivity and specificity. Direct antigen testing allows for rapid management decisions if positive, but has a low sensitivity, especially in asymptomatic patients. Active immunisation is the key to prevention and may require annual matching to circulating variants. Passive immunization with SARS-CoV-2 neutralizing anti-antibodies lost its indication due to the emergence of immune escape variants. Convalescent plasma has been proposed for passive immunization but is not readily available in most centres. For symptomatic patients, early antiviral treatment with nirmatrelvir/ritonavir or remdesivir may reduce the risk of progression to severe-critical COVID-19. Prolonged administration, repeated courses, and a combination of antivirals are considered for patients with clinical or virological failure to antiviral monotherapy. In severe-critical COVID-19, dexamethasone or drugs downregulating the inflammatory cytokine responses (anti-Il-6/anti-IL-2 agents, Janus kinase inhibitor) are recommended, together with the best supportive and intensive care, but care should be exercised in immunosuppressed patients. Deferral of intensive chemotherapy, HCT conditioning, T-cell-based immunotherapy, or T-cell engaging antibodies are considered for patients with COVID-19, whereas deferral decisions are taken on a case-by-case basis for asymptomatic patients with confirmed SARS-CoV-2 infection.
- 2 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2061-2071
Open AccessPost-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10)
In the post-pandemic years, SARS-CoV-2 morbidity and mortality declined due to less pathogenic variants, active and passive immunization, and antiviral therapies. However, patients with hematological malignancies and/or undergoing hematopoietic cell transplantation (HCT) remain at increased risk for poor outcomes. Therefore, adherence to contact and droplet precautions is essential to avoid transmission, especially during epidemic waves. Detection of viral RNA by nucleic acid testing of naso-oro-pharyngeal samples is the gold standard for diagnosis due to its high sensitivity and specificity. Direct antigen testing allows for rapid management decisions if positive, but has a low sensitivity, especially in asymptomatic patients. Active immunisation is the key to prevention and may require annual matching to circulating variants. Passive immunization with SARS-CoV-2 neutralizing anti-antibodies lost its indication due to the emergence of immune escape variants. Convalescent plasma has been proposed for passive immunization but is not readily available in most centres. For symptomatic patients, early antiviral treatment with nirmatrelvir/ritonavir or remdesivir may reduce the risk of progression to severe-critical COVID-19. Prolonged administration, repeated courses, and a combination of antivirals are considered for patients with clinical or virological failure to antiviral monotherapy. In severe-critical COVID-19, dexamethasone or drugs downregulating the inflammatory cytokine responses (anti-Il-6/anti-IL-2 agents, Janus kinase inhibitor) are recommended, together with the best supportive and intensive care, but care should be exercised in immunosuppressed patients. Deferral of intensive chemotherapy, HCT conditioning, T-cell-based immunotherapy, or T-cell engaging antibodies are considered for patients with COVID-19, whereas deferral decisions are taken on a case-by-case basis for asymptomatic patients with confirmed SARS-CoV-2 infection.
- Top Cited PapersOpen Access
- 25 February 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (4) , 864-875
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)
Myeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients’ quality of life and ability to perform daily activities. Recent studies showed differences in the perception of physician- versus patient-reported symptom burden. However, studies directly comparing patient- and physician-reported ratings are lacking. Here, a retrospective analysis on symptom burden of 3979 MPN patients of the Bioregistry of the German Study Group for MPN was conducted to intra-individually compare physician and patient reports collected at the same time. Cohen’s kappa was calculated to assess the degree of agreement between patient and physician reports. Factors influencing baseline symptom severity were identified using linear regression and adjusted Cox models were calculated to investigate the effect of symptom burden on survival. MPN patients had a high symptom burden, which neither decreased over time nor upon cytoreductive therapy. All symptoms were more frequently reported by patients compared to physicians. Agreement remained low and only slightly improved when considering a higher threshold for patient symptom severity. Patients with severe symptom burden had inferior survival compared to patients with less severe symptoms. Assessment of symptom burden in MPN is therefore insufficient and patient-reported outcome tools need to be implemented into clinical routine.
- 25 February 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (4) , 864-875
Top Cited PapersOpen AccessComparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)
Myeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients’ quality of life and ability to perform daily activities. Recent studies showed differences in the perception of physician- versus patient-reported symptom burden. However, studies directly comparing patient- and physician-reported ratings are lacking. Here, a retrospective analysis on symptom burden of 3979 MPN patients of the Bioregistry of the German Study Group for MPN was conducted to intra-individually compare physician and patient reports collected at the same time. Cohen’s kappa was calculated to assess the degree of agreement between patient and physician reports. Factors influencing baseline symptom severity were identified using linear regression and adjusted Cox models were calculated to investigate the effect of symptom burden on survival. MPN patients had a high symptom burden, which neither decreased over time nor upon cytoreductive therapy. All symptoms were more frequently reported by patients compared to physicians. Agreement remained low and only slightly improved when considering a higher threshold for patient symptom severity. Patients with severe symptom burden had inferior survival compared to patients with less severe symptoms. Assessment of symptom burden in MPN is therefore insufficient and patient-reported outcome tools need to be implemented into clinical routine.
- Top Cited PapersOpen Access
- 8 January 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (3) , 614-622
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.6 years) with R/R AML was to establish a prognostic risk score. Overall response was documented in 106 (44%) patients. With a median follow-up of 31.5 months, 179 deaths were recorded. Median overall survival (mOS) was 7.9 months. In multivariate analysis of the subgroup with molecular information (n = 174), risk factors for inferior survival included the presence of extramedullary disease, HMA pretreatment and mutations in NF1, PTPN11, FLT3, and TP53, whereas mutated SF3B1 was identified as favorable risk factor. These risk factors were subsequently applied to construct an HR-weighted risk model that allocated patients to one of three risk groups with significantly different survival outcomes: favorable (n = 46; mOS 21.4 months), intermediate (n = 75; mOS 7.5 months), and adverse (n = 53; mOS 4.6 months; p < 0.001). The model was validated in 189 AML patients treated with HMA/VEN in first line. This clinical-molecular, 3-tiered venetoclax prognostic risk score (VEN-PRS) for HMA/VEN treatment outcomes in R/R AML patients will support the selection of appropriate treatment options in this high-risk population.
- 8 January 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (3) , 614-622
Top Cited PapersOpen AccessA novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. However, predictors of outcome are elusive. The objective of the current retrospective observational multicenter study of 240 adult patients (median age 68.6 years) with R/R AML was to establish a prognostic risk score. Overall response was documented in 106 (44%) patients. With a median follow-up of 31.5 months, 179 deaths were recorded. Median overall survival (mOS) was 7.9 months. In multivariate analysis of the subgroup with molecular information (n = 174), risk factors for inferior survival included the presence of extramedullary disease, HMA pretreatment and mutations in NF1, PTPN11, FLT3, and TP53, whereas mutated SF3B1 was identified as favorable risk factor. These risk factors were subsequently applied to construct an HR-weighted risk model that allocated patients to one of three risk groups with significantly different survival outcomes: favorable (n = 46; mOS 21.4 months), intermediate (n = 75; mOS 7.5 months), and adverse (n = 53; mOS 4.6 months; p < 0.001). The model was validated in 189 AML patients treated with HMA/VEN in first line. This clinical-molecular, 3-tiered venetoclax prognostic risk score (VEN-PRS) for HMA/VEN treatment outcomes in R/R AML patients will support the selection of appropriate treatment options in this high-risk population.
- Top Cited Papers
- 23 May 2024
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 1 (6)
GPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines
- 23 May 2024
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 1 (6)
Top Cited PapersGPT-4 for Information Retrieval and Comparison of Medical Oncology Guidelines
- Open Access
- 28 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Data-driven grading of acute graft-versus-host disease
Despite advances in allogeneic hematopoietic cell transplantation, acute graft-versus-host disease (aGVHD) remains its leading complication, yet with heterogeneous outcomes. Here, we analyzed aGVHD phenotypes and clinical classifications in depth in large, multicenter cohorts involving 3019 patients and addressed prevailing gaps by developing data-driven models. We compared, tested and verified these along with all conventional classifications in independent cohorts and found that data-driven grading outperformed conventional grading in Akaike information criterion and concordance index metrics. Data-driven classifications refined aGVHD assessment with up to 12 severity grades, which were associated with distinct nonrelapse mortality (NRM) and confirmed the key role of intestinal aGVHD. We developed an online calculator for physicians to implement principal component-derived grading (PC1). These results provide substantial insight into the evaluation of aGVHD phenotypes and multiorgan involvement, which relegates the exclusive reporting of overall aGVHD severity grades in transplant registries and clinical trials. Data-driven aGVHD grading provides an expandable platform to refine classification and transplant risk assessment.
- 28 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessData-driven grading of acute graft-versus-host disease
Despite advances in allogeneic hematopoietic cell transplantation, acute graft-versus-host disease (aGVHD) remains its leading complication, yet with heterogeneous outcomes. Here, we analyzed aGVHD phenotypes and clinical classifications in depth in large, multicenter cohorts involving 3019 patients and addressed prevailing gaps by developing data-driven models. We compared, tested and verified these along with all conventional classifications in independent cohorts and found that data-driven grading outperformed conventional grading in Akaike information criterion and concordance index metrics. Data-driven classifications refined aGVHD assessment with up to 12 severity grades, which were associated with distinct nonrelapse mortality (NRM) and confirmed the key role of intestinal aGVHD. We developed an online calculator for physicians to implement principal component-derived grading (PC1). These results provide substantial insight into the evaluation of aGVHD phenotypes and multiorgan involvement, which relegates the exclusive reporting of overall aGVHD severity grades in transplant registries and clinical trials. Data-driven aGVHD grading provides an expandable platform to refine classification and transplant risk assessment.
- 20 September 2023
- Published by Springer Nature in Die Innere Medizin
- Vol. 64 (10) , 946-954
Mit einer Tumordiagnose auf der Intensivstation
- 20 September 2023
- Published by Springer Nature in Die Innere Medizin
- Vol. 64 (10) , 946-954
Mit einer Tumordiagnose auf der Intensivstation
- Open Access
MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Predictors of response to DLIs are not well established. We evaluated measurable residual disease (MRD) before, 30 and 90 days after DLI treatment as biomarkers of response. MRD was assessed by next-generation sequencing in 76 DLI-treated acute myeloid leukemia patients. MRD status before DLI treatment was independently prognostic for event-free survival (EFS, p < 0.001) and overall survival (OS, p < 0.001). Within 90 days of DLI treatment, 73% of MRD+ patients converted to MRD− and 32% of patients without remission achieved remission. MRD status 90 days after DLI treatment was independently prognostic for the cumulative incidence of relapse (CIR, p = 0.011) and relapse-free survival (RFS, p = 0.001), but not for OS. To evaluate the role of DLI treatment in MRD− patients, 23 MRD− patients who received DLIs were compared with a control cohort of 68 MRD− patients not receiving DLIs. RFS (p = 0.23) and OS (p = 0.48) were similar between the two cohorts. In conclusion, MRD is prognostic before (EFS, OS) and after (CIR, RFS) DLI treatment and may help in the selection of patients who benefit most from DLIs.
Open AccessMRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Predictors of response to DLIs are not well established. We evaluated measurable residual disease (MRD) before, 30 and 90 days after DLI treatment as biomarkers of response. MRD was assessed by next-generation sequencing in 76 DLI-treated acute myeloid leukemia patients. MRD status before DLI treatment was independently prognostic for event-free survival (EFS, p < 0.001) and overall survival (OS, p < 0.001). Within 90 days of DLI treatment, 73% of MRD+ patients converted to MRD− and 32% of patients without remission achieved remission. MRD status 90 days after DLI treatment was independently prognostic for the cumulative incidence of relapse (CIR, p = 0.011) and relapse-free survival (RFS, p = 0.001), but not for OS. To evaluate the role of DLI treatment in MRD− patients, 23 MRD− patients who received DLIs were compared with a control cohort of 68 MRD− patients not receiving DLIs. RFS (p = 0.23) and OS (p = 0.48) were similar between the two cohorts. In conclusion, MRD is prognostic before (EFS, OS) and after (CIR, RFS) DLI treatment and may help in the selection of patients who benefit most from DLIs.